Mapping the Protein Phosphatase-2B Anchoring Site on AKAP79

BINDING AND INHIBITION OF PHOSPHATASE ACTIVITY ARE MEDIATED BY RESIDUES 315–360*

Mark L. Dell’Acqua§§, Kimberly L. Dodge¶¶, Steven J. Tavaлин§§, and John D. Scott**

From the §Howard Hughes Medical Institute, Vollum Institute, Oregon Health Sciences University, Portland, Oregon 97201 and the ¶Department of Pharmacology, School of Medicine, University of Colorado Health Sciences Center, Denver, Colorado 80262

Compartmentalization of protein kinases and phosphatases with substrates is a means to increase the efficiency of signal transduction events. The A-kinase anchoring protein, AKAP79, is a multivalent anchoring protein that maintains the cAMP-dependent protein kinase, protein kinase C, and protein phosphatase-2B (PP2B/calcineurin) at the postsynaptic membrane of excitatory synapses where it is recruited into complexes with N-methyl-D-aspartic acid or α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA)-subtype glutamate receptors. We have used cellular targeting of AKAP79 truncation and deletion mutants as an assay to map the PP2B-binding site on AKAP79. We demonstrate that residues 315–360 are necessary and sufficient for AKAP79-PP2B anchoring in cells. Multiple determinants contained within this region bind directly to the A subunit of PP2B and inhibit phosphatase activity. Peptides spanning the 315–360 region of AKAP79 can antagonize PP2B anchoring in vitro and targeting in transfected cells. Electrophysiological experiments further emphasize this point by demonstrating that a peptide encompassing residues 330–357 of AKAP79 attenuates PP2B-dependent down-regulation of GluR1 receptor currents when perfused into HEK293 cells. We propose that the structural features of this AKAP79-PP2B-binding domain may share similarities with other proteins that serve to coordinate PP2B localization and activity.

The efficient transmission of cellular signals often involves the orientation of signaling proteins in relation to their upstream activators and downstream targets. This is often achieved through association with anchoring and scaffolding proteins that compartmentalize signaling enzymes in distinct subcellular environments (1–3). For example, A-kinase anchoring proteins (AKAPs) bind the regulatory (R) subunit of the cAMP-dependent protein kinase (PKA) to localize this broad specificity enzyme to discrete subcellular environments (4, 5). Each AKAP contains a conserved amphipathic helix that binds to the R subunit dimer with high affinity and targeting domains that direct the PKA-AKAP complex to specific subcellular compartments (6, 7). A likely consequence of these protein-protein interactions is that AKAP-PKA complexes are maintained in the vicinity of selected phosphoproteins and substrates for the kinase. Another important role of AKAPs is to serve as scaffolds for the assembly of multiprotein complexes that include PKA, other protein kinases, phosphodiesterases, and a variety of protein phosphatases (8). The simultaneous anchoring of kinases and phosphatases provides an efficient means to confer bi-directional control on the phosphorylation status of substrate proteins (9, 10).

A number of studies (11) have demonstrated that anchoring of kinases and phosphatases ensures the efficient regulation of ion channels and neurotransmitter receptors. One prominent mediator of this process is the multivalent anchoring protein AKAP79 that anchors PKA, protein kinase C (PKC), and protein phosphatase-2B (PP2B/calcineurin) (12–14). Precise orientation of the AKAP79 signaling complex toward substrates such as ionotropic glutamate receptors at the postsynaptic densities of neurons involves additional protein-protein interactions between the anchoring protein and membrane-associated guanylate kinase proteins. This intricate molecular architecture facilitates PKA phosphorylation at a site in the cytoplasmic tail of the GluR1 glutamate receptor channel as well as its efficient dephosphorylation by PP2B (10, 15).

Previous studies (13, 16, 17) have shown that the catalytic subunit of PP2B directly binds to sites in the C-terminal two-thirds of AKAP79 and that interaction with the anchoring protein inhibits phosphatase activity toward peptide substrates. In this report we describe experiments that map the PP2B-binding site to a region of ~45 amino acids that contains multiple binding sites and inhibitory determinants. Furthermore, we show that a peptide from this region disrupts phosphatase targeting and attenuates PP2B-dependent down-regulation of homomeric GluR1 glutamate receptor currents inside cells.

MATERIALS AND METHODS

Construction of cDNA Expression Plasmids—The cDNA for human AKAP79 was expressed from pCDNA3 (Invitrogen) constructed as described previously (16). The coding sequences for AKAP79 full-length, the C-terminal truncations shown (residues 1–360, 1–315, and 1–108), or the 321–360-binding peptide fragment were amplified by PCR using specific synthetic oligonucleotide primers. The PCR products introduced a 5’ HindIII site, consensus ribosome-binding site, an ATG initiation codon, and a BamHI site at the 3’ end of the coding region. Each fragment was subcloned as a HindIII-BamHI fragment into pEGFPN1 (Clontech) to generate C-terminal fusions to EGFP. Internal deletions of AKAP79-Δ(109–315), -(109–360), -(151–315), -(151–360), -(315–360), -(328–338), -(348–360), and -(328–360) were gener-

* This work was supported in part by Scientist Development Grant AHA-SDG 0130228N from the American Heart Association (to M. L. D.) and National Institutes of Health Grant GM48231 (to J. D. S.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

† Two authors contributed equally to this work.

§ Present address: Dept. of Pharmacology, College of Medicine, University of Tennessee Health Science Center, Memphis, TN 38163.

** To whom correspondence should be addressed. E-mail: scott@ohsu.edu.

¶¶ The abbreviations used are: AKAP, A-kinase anchoring proteins; PKA, cAMP-dependent protein kinase; PKC, protein kinase C; PP2B, protein phosphatase-2B; AMPA, α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid; BSA, bovine serum albumin; PBS, phosphate-buffered saline; GFP, green fluorescent protein; EGFP, enhanced GFP.
immune complexes were isolated by incubation with 5 μg/H9262 per cell. This was performed as described previously (14).

The washed coverslips were mounted on glass slides and analyzed using either a Zeiss Axiovert TV-135 inverted microscope, a Nikon TE-300, or goat anti-rabbit-Cy5, Molecular Probes) for 1 h at room temperature. The washed coverslips were mounted on glass slides and analyzed using a either a Zeiss Axiovert TV-135 inverted microscope (63x, oil, 1.4 NA) equipped with a digital CCD camera (Sensorys) and Meta-GFP imaging software (Universal Imaging) or a Nikon TE-300 inverted microscope (100x, plan-apo, oil, 1.4 NA) equipped with a digital CCD camera (Princeton Instruments) and Slidebook 3.0 imaging software (Intelligent Imaging Innovations). The coverslips were then visualized using enhanced chemiluminescence (ECL; Pierce) and Kodak X-Omat AR film. Immunoblots were then visualized using anti-PP2B A subunit antibodies. Immunoblots were then visualized using anti-PP2B A subunit antibodies. The coding region of the A subunit of mouse PP2B was amplified by PCR using oligonucleotide primers. This introduced a BamHI at the 5’ end and a 3’ EcoRI site in place of the stop codon. A fragment with BamHI and EcoRI ends was subcloned into pCDNA3.1MycHis(A+N) (Invitrogen) to generate a C-terminal Myc epitope fusion.

Immunoprecipitation—COS7 cells were transfected by adherence of CD4 antibody-coated beads 24 h after transfection.

GFP epifluorescence was used to confirm expression of AKAP79 in these cells. Whole-cell recordings were made with an Axopatch 200B amplifier (Axon Instruments). Patch pipettes (2–4 megalohms) contained 140 mM cesium methanesulfonate, 10 mM HEPES, 5 mM adenine triphosphate (sodium salt), 5 mM MgCl₂, 0.2 mM CaCl₂, and 1.2 mM bis-2-aminoethoxyethane-N,N,N’,N’-tetraacetic acid (pH 7.4). The 330-357-residue peptide was added to the pipette solution from frozen concentrated stocks. The extracellular solution contained 150 mM NaCl, 5 mM KCl, 1.8 mM CaCl₂, 10 mM HEPES, 10 mM glucose (pH 7.4). Solution exchanges were accomplished through a series of flow pipes. Flow pipes were controlled by solenoid valves and moved into position by a piezoelectric bimorph. HEK293 cells were lifted off the bottom of the dish to speed the solution exchange time. GluR1 receptor currents were evoked by a 500-ms application of glutamate in the presence of cyclothiazide (100 μM) at 30-s intervals. Currents were digitized at 5 kHz and filtered at 1 kHz with a Digidata 1200B board and Clampex 7 software (Axon Instruments). Series resistance (85–95%) and whole-cell capacitance compensation were used and routinely monitored throughout the experiments. Only HEK293 cells with series resistance <5 meghoms were analyzed. All experiments were performed within 1 min of establishing whole-cell configuration and performed at a holding potential of −60 mV at 20 °C.

RESULTS

**AKAP79 Mediates Plasma Membrane Targeting of PP2B in Transfected COS7 Cells**—As a prelude to detailed mapping studies, we tested whether expression of recombinant AKAPs could target PP2B to the plasma membrane. In COS7 cells, the cellular distribution of PP2B and selected AKAPs was visual-
ized by immunocytochemical techniques (Fig. 1). Control experiments show that transient expression of a C-terminal Myc-tagged A subunit of PP2B results in a cytoplasmic distribution of the phosphatase (Fig. 1, A–C). In contrast, expression of AKAP79 results in an accumulation of the anchoring protein at the plasma membrane in cortical ruffles (Fig. 1, D). Similar results were obtained upon expression of an AKAP79-green fluorescent protein fusion protein (GFP), suggesting that the addition of the fluorescent moiety did not affect cellular targeting of the anchoring protein or perturb interaction with the phosphatase (Fig. 1, G–I). Further controls demonstrated that expression of another membrane-targeted anchoring protein, AKAP18-GFP, had no effect on the cytoplasmic localization of PP2B (Fig. 1, J–L). Collectively, these experiments demonstrate that AKAP79 participates in directing the subcellular location of PP2B in COS7 cells.

Mapping the PP2B-binding Site on AKAP79—Previous studies (16, 17) have demonstrated that the C-terminal two-thirds of AKAP79 (residues 108–427) are sufficient to bind PP2B in vitro and in COS7 cells. In order to map further the PP2B-binding site on AKAP79, we sequentially deleted C-terminal regions of the anchoring protein, and we tested the ability of these recombinant GFP fusion proteins to interact with the phosphatase in COS7 cells (Fig. 2). Only the longest fragment, AKAP79-(1–360), retained the ability to interact with the phosphatase (Fig. 2, B–D). Two shorter fragments, AKAP79-(1–315) and AKAP79-(1–108), did not alter the subcellular location of the phosphatase (Fig. 2, E–G and H–J). These results imply that residues 315–360 of the anchoring protein are necessary for interaction with PP2B. This notion was further supported by cellular analysis of additional AKAP79 constructs where internal sections of the anchoring protein were removed (Fig. 2, A). Deletion of residues 151–315 generated an AKAP79 form that retained the ability to target the phosphatase (Fig. 2, K–M), whereas removal of residues 151–360 abolished interaction with PP2B (Fig. 2, N–P). These results confirm that residues 315–360 of AKAP79 are necessary for interaction with PP2B. In order to determine whether this region was sufficient for phosphatase binding, a further construct, AKAP79-(315–360), was generated (Fig. 2A). This internally truncated version of the anchoring protein was unable to alter PP2B location when expressed in COS7 cells (Fig. 2, Q–S), suggesting that a 45-amino acid segment

Fig. 2. Residues 315–360 of AKAP79 are necessary for targeting of PP2B in COS7 cells. A, schematic diagram of the AKAP79 fragments used to analyze PP2B localization in COS7 cells. The first and last residue of each construct and the positions of internal deletions are indicated. GFP was fused at the C terminus of each fragment. The approximate location of the PKA (blue) and PKC (cyan)-binding sites and subcellular targeting domains (green) are indicated. Constructs capable of targeting PP2B (filled boxes) are indicated. B–S, COS7 cells transfected with myc-PP2B catalytic subunit and a variety of anchoring protein constructs. Cells were fixed, immunostained, and imaged to visualize the location of each AKAP79 fragment (green) and Myc-PP2B (red). Analysis was performed on an inverted microscope with a digital CCD camera. Overlay of the green and red signals is seen as yellow in the composite images. B–D, characterization of the AKAP79-(1–360) fragment. E–G, characterization of the AKAP79-(1–315) fragment. H–J, characterization of the AKAP79-(1–108) fragment. K–M, characterization of the AKAP79-(151–315) fragment. N–P, characterization of the AKAP79-(151–360) fragment. Q–S, characterization of the AKAP79-(315–360) fragment.
between residues 315 and 360 of the anchoring protein is required for PP2B targeting.

Independent biochemical support for our cellular mapping studies was obtained by co-immunoprecipitation of AKAP79-PP2B complexes from COS7 cells (Fig. 3). Cells were transfected with Myc-tagged A subunit of PP2B and selected AKAP79 forms (Fig. 3A). Efficient expression of each recombinant AKAP form was confirmed by immunoblotting cell extracts with anti-AKAP79 polyclonal antibody (Fig. 3B). The ability of each AKAP79-fusion protein to associate with the Myc-tagged A subunit of PP2B was evaluated by immunoprecipitation with anti-Myc monoclonal antibody. As expected, AKAP79 and the 1–360-residue fragment co-precipitated with PP2B (Fig. 3B, left and center left panels), whereas the 1–315- and the Δ315–360-residue forms did not (Fig. 3B, center right and right panels). Control experiments confirmed that none of the AKAP79 forms were present in immune complexes isolated with an unrelated IgG (Fig. 3B). These data use an independent approach to imply further that determinants between residues 315–360 of AKAP79 are necessary for PP2B binding.

**Direct in Vitro Binding of PP2B to an AKAP79(330–357) Peptide**—A series of three overlapping peptides spanning the 315–360-region of AKAP79 were synthesized to establish whether these residues were responsible for direct binding and inhibition of phosphatase activity (Fig. 4A). In vitro pulldown assays were performed to test whether each peptide bound to recombinant A subunit of PP2B (Fig. 4B). Each peptide bound to the phosphatase, whereas control experiments performed with a 24-residue peptide of similar amino acid composition were negative (Fig. 4B). Because the AKAP79-(318–338) and the AKAP79-(338–357) peptides encompass different segments of the PP2B-binding site, it is suggested that phosphatase-binding determinants are dispersed throughout this region of the anchoring protein (Fig. 4B).

Previous studies (13, 16) have shown that AKAP79 inhibits PP2B activity in a dose-dependent manner. Therefore, each PP2B-binding peptide was assayed as an inhibitor of the phosphatase using a PKA-phosphorylated substrate peptide (18). Recombinant AKAP79 inhibits PP2B activity in a dose-dependent manner with an IC_{50} value of 5.3 ± 0.5 μM (n = 3) (Fig. 4C, open squares). All three peptides also inhibit PP2B activity over the same concentration range, with IC_{50} values of 3.2 ± 0.17 μM (n = 3) for the 318–338-residue peptide (Fig. 4C, circles), 1.5 ± 0.45 μM (n = 3) for the 338–357-residue peptide (Fig. 4C, triangles), and 1.5 ± 0.2 μM (n = 3) for the 330–357-residue peptide (Fig. 4C, squares). Incubation with a 24-residue control peptide of similar amino acid composition did not affect phosphatase activity (Fig. 4C, diamonds). Collectively, these experiments suggest that these are at least two sites between residues 318 and 357 of AKAP79 that bind PP2B and inhibit phosphatase activity. The presence of multiple PP2B-binding determinants in this region was confirmed by analysis of three additional AKAP79 deletion mutants in COS7 cells (data not shown). Removal of residues 328–338 or residue 348–360 from the anchoring protein resulted in decreased Myc-PP2BA targeting to the plasma membrane, whereas deletion of residues 328–360 completely abolished PP2B anchoring.

The 330–357 Peptides Are Antagonists of PP2B/AKAP79 I-
Fig. 5. The PP2B-binding region of AKAP79 antagonizes phosphatase interaction with the anchoring protein. A, purified AKAP79 and PP2B holoenzymes were incubated in vitro with increasing concentrations (0–10 μM) of 330–357 peptide or unrelated control peptide (10 μM, Ht31 PKA-R-binding peptide). PP2B binding to AKAP79 was then analyzed by immunoprecipitation (IP) with anti-AKAP79. Top panel, co-purification of PP2B in the presence of increasing AKAP79-(330–357) peptide (indicated above each lane) was detected by immunoblotting with polyclonal antibodies against the phosphatase. The migration position of the A subunit of PP2B is indicated. The migration position of the A subunit of PP2B is indicated.

B, immunoblots from four independent experiments were analyzed densitometrically using NIH image software for quantification. Values on the y axis are normalized (set at 1.0) to the amount of PP2B immunoprecipitated with AKAP79 in the absence of peptide. Normalized intensity values are represented as the mean ± S.D. across all experiments. The concentration of the AKAP79-(330–357) peptide is indicated below each column. C, schematic diagram depicting the region of AKAP79 used to generate a soluble GFP fusion protein for cellular expression in COS7 cells. The first and last residues of the anchoring protein, and PP2B holoenzymes were incubated in vitro with increasing AKAP79-(330–357)-GFP fusion protein (indicated above each lane) was detected by immunoblotting with polyclonal antibodies against the phosphatase. The migration position of AKAP79 is indicated. The migration position of AKAP79 is indicated.

B, AKAP79-(330–357) peptide (indicated above each lane) was detected by immunoblotting with polyclonal antibodies against the phosphatase. The migration position of AKAP79 is indicated. The migration position of AKAP79 is indicated. The migration position of AKAP79 is indicated. 

C, schematic diagram depicting the region of AKAP79 used to generate a soluble GFP fusion protein for cellular expression in COS7 cells. The first and last residues of the anchoring protein, and PP2B holoenzymes were incubated in vitro with increasing AKAP79-(330–357)-GFP fusion protein (indicated above each lane) was detected by immunoblotting with polyclonal antibodies against the phosphatase. The migration position of AKAP79 is indicated. The migration position of AKAP79 is indicated. The migration position of AKAP79 is indicated. 

D, PP2B was measured by quantitative Western blot (Fig. 5, A, middle panel). Cellular expression of the AKAP79-(321–360)-GFP fusion protein is sufficient to disrupt PP2B/AKAP interaction inside cells. Cell bodies were transfected with control plasmid or the AKAP79-(321–360)-GFP construct. Both samples were also transfected with vectors encoding full-length AKAP79 and the A subunit of PP2B. Transfected cells were then fixed, stained, and analyzed by triple-fluorescence microscopy for GFP (green) (D and H). AKAP79-Cy5 (blue) (E and I), and PP2B-Texas Red (red) (F and J). G and K, an overlay of all three fluorescence channels is shown in the composite panel.

Finding indicate that overexpression of the untargeted AKAP79-(321–360) peptide disrupts plasma membrane anchoring of PP2B, suggesting that this region of the anchoring protein is sufficient to disrupt the cellular targeting of the phosphatase inside cells.

The AKAP79-(330–357) Peptide Disrupts PP2B Function Inside Cells—Recent data suggest that AKAP79 is likely to coordinate the phosphorylation state and activity of the AMPA-type glutamate receptor ion channels (10, 15). Co-expression of AKAP79 with GluR1 subunit of the AMPA receptor leads to a time-dependent down-regulation (rundown) of recombinant GluR1 receptor currents expressed in HEK293 cells. This effect is contingent on a rise in intracellular calcium and PP2B activity (10). For these reasons we chose to test the effects of the AKAP79-(330–357) peptide on homomeric GluR1 receptor currents expressed in HEK293 cells (Fig. 6). Whole-cell patch clamp recording techniques were used to recapitulate the AKAP79-dependent rundown of GluR1 receptor currents (Fig. 6). Expression of AKAP79 promoted a reduction to 64.8 ± 5.6% of initial current, n = 7, p < 0.01 GluR1 current over a 15-min period (Fig. 6, open triangles) when compared with controls (Fig. 6, open circles, 86.2 ± 5.8% of initial current, n = 6). However, when the AKAP79-(330–357) peptide was included in the whole-cell pipette solution, this AKAP79-dependent rundown of GluR1 receptor currents was blunted to 83.5 ± 5.6% of initial current, n = 7 p > 0.3 (Fig. 6, closed triangles). Most important, control cells expressing GluR1 alone were unaffected by the peptide (Fig. 6, closed circles, 90.7 ± 3.9% of initial current, n = 7 p > 0.3). These results indicate that the AKAP79-(330–357) peptide disrupts a cellular function attributed to AKAP79-anchored PP2B inside cells.
Mapping the Protein Phosphatase-2B Anchoring Site on AKAP79

DISCUSSION

We have mapped a region in the neuronally expressed anchoring protein AKAP79 that is necessary for binding and inhibiting the calcium/calmodulin-dependant phosphatase PP2B/calcineurin. A combination of biochemical and enzymatic approaches has identified multiple binding and inhibitory determinants that are located between residues 318 and 357 of the anchoring protein. Our characterization of this PP2B-binding region is the latest in a series of studies that have dissected functional regions within AKAP79 that are responsible for the interaction with distinct signaling enzymes. Residues 391–408 form an amphipathic helix that binds to the R subunit dimer of the PKA holoenzyme with nanomolar affinity (7, 12, 19). Peptides spanning this region have been used by many investigators to disrupt a variety of CaM-responsive events by uncoupling PKA location inside cells (20–25). A PKC-binding site is located between residues 31 and 52 (14). Peptides spanning this region bind to the kinase with micromolar affinities and inhibit the bound enzyme. This effect is reversed by calcium/calmodulin, which competes for interaction with the 31–52 region and releases the active kinase from the signaling complex at the postasynaptic densities of neurons (26, 27).

In this report, we demonstrate that a family of peptides synthesized to regions of the anchoring protein between residues 318 and 357 disrupt the subcellular location of the phosphatase and inhibit PP2B-dependent phosphorylation events. Another region of AKAP79 within the membrane targeting domain (residues 88–102) may also participate in PP2B anchoring (13, 16, 17), although the inhibitory potency of peptides to this site is ~50-fold less than the AKAP79-(330–357) peptide, and they cannot displace the phosphatase from its sites of anchoring. Therefore, we propose that the region between residues 318 and 357 is likely to contain most of the high affinity determinants for PP2B anchoring. This postulate is consistent with recent reports (17, 28, 29) that recombinant fragments of AKAP79 that include this region inhibit PP2B signaling events in transfected cells and transgenic mice. Interestingly, the AKAP79-(330–357) and AKAP79-(338–357) peptides are slightly more potent inhibitors of the phosphatase than the full-length anchoring protein. Similarly, we have observed that protein fragments of AKAP79 sometimes work more efficiently than the full-length protein. For example, residues 108–427 inhibit PP2B more effectively than the full-length protein (16). Likewise, the first 75 amino acids of the anchoring protein is a more potent inhibitor of PKC activity than the full-length protein (14).

The AKAP79-(318–357) sequence exhibits some similarity to the binding sites of other PP2B-interacting proteins. For example, the organization of serines, threonines, and the clustering of basic amino acids in this region is reminiscent of the 38-residue PP2B-binding region in Cain, (calcineurin inhibitor)/cabin (30, 31). Both proteins are non-competitive inhibitors of PP2B activity that inhibit the phosphatase in the low micromolar range and bind PP2B at a site distinct from the immunosuppressant drugs FK506 and cyclosporin A (13, 17, 32). Another common characteristic is the presence of a loosely conserved “PIXLIXIT” motif (where X represents any amino acid). This sequence was first identified in the transcription factor NFATc and has been found in the docking sites of other PP2B interacting partners including Cain/cabin and the muscle-specific protein MCIP1,2 (33–35). Residues 337–343 of AKAP79 (PI[ALT]IT) form the PIXLIXIT motif, and it is totally conserved in the murine and bovine orthologs, AKAP150 and AKAP75 (36–38). Although not formally proven, it is likely that this sequence represents a principle site of contact with the phosphatase, because the AKAP79-(330–357) peptide, which includes this region, inhibits phosphatase activity at micromolar concentrations and competes for binding with the intact anchoring protein. However, it is clearly evident that other regions of AKAP79 contribute to PP2B interactions as peptides upstream of the PIXLIXIT motif also bind and inhibit the phosphatase. These findings are certainly consistent with the notion that multiple determinants located in a central segment of the AKAP79 linear sequence act in tandem to anchor PP2B and inhibit phosphatase activity inside cells. Apparently multisite contact between phosphatases and their binding partners is a common theme in the subcellular targeting of this enzyme class, as a second PP2B-binding site has been defined within the regulatory domain of NFATc which may act synergistically with the PIXLIXIT motif to permit a high affinity interaction with the phosphatase (39). Similarly, there are examples of type 1 phosphatase targeting subunits that interact with the catalytic subunit (PP1c) through multiple sites (40, 41).

One goal of our study was to generate peptide-based antagonists of PP2B function inside cells. Accordingly, we have shown that perfusion of the AKAP79-(330–357) peptide prevents the attenuation of GluR1 type AMPA channels by the AKAP79 signaling complex in HEK293 cells. We have shown previously that AKAP79-mediated anchoring of PP2B confers a calcium-dependent rundown of the channel through the dephosphorylation of serine 845, a site in the cytoplasmic tail of the GluR1 subunit (10). Basal phosphorylation of Ser-845 is maintained by anchored PKA, suggesting that AKAP79 contributes to the regulation of this channel by positioning kinases and phosphates in close proximity to a subset of their substrates (10, 11, 15, 42–45). Our electrophysiological measurements infer that perfusion of the AKAP79-(330–357) peptide shifts the equilibrium in favor of the phosphorylated state of GluR1. Importantly, our control experiments demonstrate that this peptide is only active in the presence of AKAP79, thereby indicating that PP2B targeting ensures efficient modulation of GluR1 currents. Yet our experiments are unable to delineate the mechanism of action of this peptide. Our biochemical analyses would suggest that it must function by displacing PP2B from its site of action and/or as an inhibitor of the anchored phosphatase. Nonetheless, our experiments highlight the util-

**Fig. 6.** The AKAP79-(330–357) peptide disrupts PP2B-dependent modulation of GluR1 receptor currents by AKAP79. HEK293 cells were transfected with GluR1 alone (control) or with AKAP79. Whole-cell GluR1 receptor currents were evoked by glutamate (1 mM) in the presence of cyclothiazide (100 μM). GluR1 receptor currents selectively rundown when co-expressed with AKAP79 (open triangles) compared with control cells (open circles). Whole-cell dialysis of the 330–357 peptide (10 μM) into cells blunts the AKAP79-dependent rundown (filled triangles), whereas it is without effect in control cells (filled circles). Side panels show representative traces, and parentheses denote number of observations for each condition at time 0 and 15 min.
ity of this reagent as a cell-based modulator of PP2B. Likewise, Cain has also been used to perturb PP2B function inside cells, as it binds the endocytic machinery through amphiphysin 1 to negatively regulate PP2B/dynamin-dependent synaptic vesicle endocytosis (30, 32). Thus it is tempting to speculate that AKAP79 anchoring and inhibition of PP2B might function in a concerted manner to modulate not only AMPA receptor currents but also to attenuate the phosphorylation events that control receptor endocytosis.

Acknowledgments—We thank Brian Nauert for pCDNA3 PP2B vectors; Iain Fraser for pCDNA AKAP18-GFP; Yvonne Lai (ICOS Corp.) for anti-AKAP79 rabbit polyclonal antiserum (9181); and Lisa L. Gomez and Shuvo Alam for technical assistance.

REFERENCES

1. Pawson, T., and Scott, J. D. (1997) Science 278, 2075–2080
2. Jordan, J. D., Landsau, E. M., and Iyengar, R. (2000) Cell 103, 193–200
3. Hunter, T. (2000) Cell 100, 113–127
4. Collede, M., and Scott, J. D. (1999) Trends Cell Biol. 9, 216–221
5. Feliciello, A., Gottesman, M. E., and Avvedimento, E. V. (2001) J. Mol. Biol. 308, 99–114
6. Carr, D. W., Stolfo-Hahn, R. E., Fraser, I. D. C., Bishop, S. M., Acott, T. S., DeWindt, L. J., and Molkentin, J. D. (1999) J. Biol. Chem. 274, 14188–14192
7. Newlan, M. G., Roy, M., Morikis, D., Carr, D. W., Westphal, R., Scott, J. D., and Jennings, P. A. (2001) EMBO J. 20, 1651–1662
8. Smith, F. D., and Scott, J. D. (2002) Curr. Biol. 12, R32–R40
9. Westphal, R. S., Tavalian, S. J., Lin, J. W., Alu, N. M., Fraser, I. D., Langeberg, L. K., Sheng, M., and Scott, J. D. (1999) J. Biol. Chem. 274, 93–96
10. Tavalin, S. J., Collede, M., Hell, J. W., Langeberg, L. K., Huganir, R. L., and Scott, J. D. (2002) J. Neurosci. 22, 3044–3051
11. Fraser, I. D., and Scott, J. D. (1999) Neuron 23, 423–426
12. Carr, D. W., Stolfo-Hahn, R. E., Fraser, I. D. C., Coghlan, V. M., and Scott, J. D. (1999) J. Biol. Chem. 274, 16916–16923
13. Coghlan, V. M., Perrino, B. A., Howard, M., Langeberg, L. K., Hicks, J. B., Gallatin, W. M., and Scott, J. D. (1995) Science 267, 108–112
14. Klauck, T. M., Faux, M. C., Labudda, K., Langeberg, L. K., Jaken, S., and Scott, J. D. (1996) Science 271, 1589–1592
15. Collede, M., Dean, R. A., Scott, G. K., Langeberg, L. K., Huganir, R. L., and Scott, J. D. (2000) Neuron 27, 107–119
16. Dell’Aquila, M. L., Faux, M. C., Thorburn, J., Thorburn, A., and Scott, J. D. (1998) EMBO J. 17, 2246–2260
17. Kashishian, A., Howard, M., Lai, J., Gallatin, W. M., Hoekstra, M. F., and Lai, Y. (1998) J. Biol. Chem. 273, 27412–27419
18. Blumenthal, D., Takis, K., Hansen, R. S., and Krebs, E. G. (1986) J. Biol. Chem. 261, 8140–8145
19. Hausten, Z. E., Dell’Aquila, M. L., Coghlan, V. M., and Scott, J. D. (1996) J. Biol. Chem. 271, 28916–28922
20. Rosenmund, C., Carr, D. W., Bergeson, S. E., Nilsaver, G., Scott, J. D., and Westbrook, G. L. (1994) Nature 368, 853–856
21. Lester, L. B., Langeberg, L. K., and Scott, J. D. (1997) Proc. Natl. Acad. Sci. U. S. A. 94, 14482–14484
22. Fink, M. A., Zakhary, D. R., Mackey, J. A., Desnoyer, R. W., Apperson-Hansen, C., Damron, D. S., and Bond, M. (2001) Circ. Res. 88, 291–297
23. Feliciello, A., Li, Y., Avvedimento, E. V., Gottesman, M. E., and Rubin, C. S. (1997) Curr. Biol. 7, 1011–1014
24. Sun, F., Hug, M. J., Bradbury, N. A., and Frizzell, R. A. (2000) J. Biol. Chem. 275, 14360–14366
25. Dodge, K. L., Carr, D. W., and Sanborn, B. M. (1999) Endocrinology 140, 5165–5170
26. Faux, M. C., and Scott, J. D. (1997) J. Biol. Chem. 272, 17038–17044
27. Faux, M. C., Rollins, E. N., Edwards, A. S., Langeberg, L. K., Newton, A. C., and Scott, J. D. (1999) Biochem. J. 345, 443–452
28. Taiten, T., De Windt, L. J., Lim, H. W., and Molkentin, J. D. (2000) Proc. Natl. Acad. Sci. U. S. A. 97, 1196–1201
29. De Windt, L. J., Lim, H. W., Bueno, O. F., Liang, Q., Delling, U., Braz, J. C., Glasscock, B. J., Kimball, T. F., del Monte, F., Hajjar, R. J., and Molkentin, J. D. (2001) Proc. Natl. Acad. Sci. U. S. A. 98, 3322–3327
30. Lai, M. M., Burnett, P. E., Wolsker, H., Blackshaw, S., and Snyder, S. H. (1998) J. Biol. Chem. 273, 18325–18331
31. Luo, S., Youn, H.-D., Loh, C., Stolow, M., He, W., and Liu, J. O. (1998) Immunity 8, 603–711
32. Lai, M. M., Lur, H. R., Burnett, P. E., Hong, J. J., and Snyder, S. H. (2000) J. Biol. Chem. 275, 34017–34020
33. Arambruz, J., Garcia-Cazor, F., Raghavan, A., Okamura, H., Rao, A., and Hogan, P. G. (1998) Mol. Cell 1, 627–637
34. Arambruz, J., Yaffe, M. B., Lopez-Rodriguez, C., Cantley, L. C., Hogan, P. G., and Rao, A. (1999) Science 285, 2129–2133
35. Rothermel, B., Vega, K. B., Yang, J. W., Wu, H., Bassel-Duby, R., and Williams, R. S. (2000) J. Biol. Chem. 275, 8719–8725
36. Bregman, D. B., Bhattacharrya, N., and Rubin, C. S. (1989) J. Biol. Chem. 264, 4648–4656
37. Bregman, D. B., Hirsch, A. H., and Rubin, C. S. (1991) J. Biol. Chem. 266, 7207–7213
38. Hirsch, A. H., Glantz, S. B., Li, Y., You, Y., and Rubin, C. S. (1992) J. Biol. Chem. 267, 2131–2134
39. Park, S., Uessei, M., and Verdin, G. L. (2000) Proc. Natl. Acad. Sci. U. S. A. 97, 7130–7135
40. Allen, P. B., Dec, Y. G., Nairn, A. C., and Greengard, P. (1998) J. Biol. Chem. 273, 4095–4098
41. Schillace, R. V., Voltz, J. W., Sim, A. T., Shenolikar, S., and Scott, J. D. (2001) J. Biol. Chem. 276, 12128–12134
42. Swype, S. E., Moss, S. L., Raymond, L. A., and Huganir, R. L. (1999) Adv. Second Messenger Phosphoprotein Res. 33, 49–78
43. Kameyama, K., Lee, H. K., Bear, M. F., and Huganir, R. L. (1998) Neuron 21, 1163–1175
44. Lee, H. K., Kameyama, K., Huganir, R. L., and Bear, M. F. (1998) Neuron 21, 1151–1162
45. Lee, H. K., Barbarosie, M., Kameyama, K., Bear, M. F., and Huganir, R. L. (2000) Nature 405, 855–859